CDIO (Cardio Diagnostics Holdings) Interest Coverage : 0 (At Loss) (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Cardio Diagnostics Holdings Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Cardio Diagnostics Holdings's Operating Income for the three months ended in Dec. 2024 was $-1.52 Mil. Cardio Diagnostics Holdings's Interest Expense for the three months ended in Dec. 2024 was $-0.00 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Cardio Diagnostics Holdings's Interest Coverage or its related term are showing as below:

CDIO's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 112.88
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cardio Diagnostics Holdings Interest Coverage Historical Data

The historical data trend for Cardio Diagnostics Holdings's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cardio Diagnostics Holdings Interest Coverage Chart

Cardio Diagnostics Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Coverage

No Debt

Cardio Diagnostics Holdings Quarterly Data
	Dec20	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Coverage	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of Cardio Diagnostics Holdings's Interest Coverage

For the Biotechnology subindustry, Cardio Diagnostics Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardio Diagnostics Holdings's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Cardio Diagnostics Holdings's Interest Coverage falls into.

Save Embed

;

Save Embed

;

Cardio Diagnostics Holdings Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cardio Diagnostics Holdings's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Cardio Diagnostics Holdings's Interest Expense was $-0.02 Mil. Its Operating Income was $-8.37 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.43 Mil.

Cardio Diagnostics Holdings did not have earnings to cover the interest expense.

Cardio Diagnostics Holdings's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Here, for the three months ended in Dec. 2024, Cardio Diagnostics Holdings's Interest Expense was $-0.00 Mil. Its Operating Income was $-1.52 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.43 Mil.

Cardio Diagnostics Holdings did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

Cardio Diagnostics Holdings (NAS:CDIO) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Cardio Diagnostics Holdings Interest Coverage Related Terms

Thank you for viewing the detailed overview of Cardio Diagnostics Holdings's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardio Diagnostics Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardio Diagnostics Holdings Inc (NAS:CDIO) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

311 West Superior Street, Suite 444, Chicago, IL, USA, 60654

Website

https://www.cdio.ai

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.

Executives

Robert Philibert	director, 10 percent owner, officer: Chief Medical Officer	400 N. ABERDEEN, SUITE 900, CHICAGO IL 60642
Timur Dogan	officer: Chief Technology Officer	400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Meeshanthini Dogan	director, 10 percent owner, officer: Chief Executive Officer	400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Warren Hosseinion	director	C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801
Elisa V Luqman	officer: Chief Financial Officer	37 HARRISON DRIVE, NORTHPORT NY 11768
Khullani Abdullahi	officer: VP of Revenue and Strategy	400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Brandon Sim	director	C/O APOLLO MEDICAL HOLDINGS, INC., 1668 S. GARFIELD AVENUE, 3RD FLOOR, ALHAMBRA CA 91801
James Intrater	director	C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Oded Levy	director	C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Stanley K. Lau	director	C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Bd Holding, Inc.	10 percent owner	15 PROSPECT PLACE, IOWA CITY IA 52246
Jonathan Intrater	officer: CEO	223 PALMER STREET, PALMER MA 01069
Allan Liu	director	1600 PARKWOOD CIRCLE, STE 200, ATLANTA GA 30339-2119
Loren Mortman	director	207 EAST 74TH STREET, APARTMENT 10F, NEW YORK NY 10021
Mana Capital Llc	10 percent owner	8 THE GREEN, SUITE A, DOVER DE 19901